Nervgen Pharma Corp Stock Performance
| NGEN Stock | CAD 2.87 0.08 2.87% |
NervGen Pharma has a performance score of 3 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.55, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, NervGen Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding NervGen Pharma is expected to be smaller as well. NervGen Pharma Corp right now secures a risk of 4.65%. Please verify NervGen Pharma Corp maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to decide if NervGen Pharma Corp will be following its current price movements.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in NervGen Pharma Corp are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating technical and fundamental indicators, NervGen Pharma may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
1 | NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science Advocacy Symposium Focused on Spinal Cord Injury - StockTitan | 09/20/2024 |
| Begin Period Cash Flow | 22.5 M |
NervGen |
NervGen Pharma Relative Risk vs. Return Landscape
If you would invest 272.00 in NervGen Pharma Corp on September 2, 2024 and sell it today you would earn a total of 15.00 from holding NervGen Pharma Corp or generate 5.51% return on investment over 90 days. NervGen Pharma Corp is generating 0.1923% of daily returns assuming 4.6511% volatility of returns over the 90 days investment horizon. Simply put, 41% of all stocks have less volatile historical return distribution than NervGen Pharma, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
NervGen Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NervGen Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NervGen Pharma Corp, and traders can use it to determine the average amount a NervGen Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0413
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NGEN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.65 actual daily | 41 59% of assets are more volatile |
Expected Return
| 0.19 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average NervGen Pharma is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NervGen Pharma by adding it to a well-diversified portfolio.
NervGen Pharma Fundamentals Growth
NervGen Stock prices reflect investors' perceptions of the future prospects and financial health of NervGen Pharma, and NervGen Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NervGen Stock performance.
| Return On Equity | -2.3 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 180.91 M | ||||
| Shares Outstanding | 70.31 M | ||||
| Price To Book | 21.99 X | ||||
| EBITDA | (19.24 M) | ||||
| Net Income | (22.38 M) | ||||
| Cash And Equivalents | 8.27 M | ||||
| Cash Per Share | 0.30 X | ||||
| Total Debt | 15.25 M | ||||
| Current Ratio | 25.72 X | ||||
| Book Value Per Share | (0.03) X | ||||
| Cash Flow From Operations | (11.3 M) | ||||
| Earnings Per Share | (0.38) X | ||||
| Market Capitalization | 201.78 M | ||||
| Total Asset | 13.24 M | ||||
| Retained Earnings | (78.15 M) | ||||
| Working Capital | (2.62 M) | ||||
About NervGen Pharma Performance
Evaluating NervGen Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NervGen Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NervGen Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.76) | (1.85) | |
| Return On Capital Employed | 9.34 | 9.81 | |
| Return On Assets | (1.69) | (1.78) | |
| Return On Equity | 11.14 | 11.70 |
Things to note about NervGen Pharma Corp performance evaluation
Checking the ongoing alerts about NervGen Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NervGen Pharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NervGen Pharma Corp had very high historical volatility over the last 90 days | |
| NervGen Pharma Corp has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NervGen Pharma Corp has accumulated about 8.27 M in cash with (11.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3. | |
| Roughly 23.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing NervGen Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NervGen Pharma's stock is overvalued or undervalued compared to its peers.
- Examining NervGen Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NervGen Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NervGen Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NervGen Pharma's stock. These opinions can provide insight into NervGen Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NervGen Stock Analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.